Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enwei Pharmaceutical CoSZSE:301331 -0.86%76 Quick Ratio is 2.03 as of Mar. 2026, which is 36% below its 10-year median of 3.15. GuruFocus rates SZSE:301331 with a GF Score™ of 76/100 and a GF Value™ of ¥28.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Enwei Pharmaceutical Co ranks better than 65.43% on this metric.
Enwei Pharmaceutical Co (SZSE:301331) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Enwei Pharmaceutical Co Quick Ratio Related Terms
Enwei Pharmaceutical Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enwei Pharmaceutical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enwei Pharmaceutical Co Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enwei Pharmaceutical Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Enwei Pharmaceutical Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Enwei Pharmaceutical Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enwei Pharmaceutical Co (SZSE:301331) has a Quick Ratio of 2.03 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Enwei Pharmaceutical Co and its competitors. This is 36% below median its historical median of 3.15. Over the past decade, Enwei Pharmaceutical Co's Quick Ratio has ranged from 0.74 to 4.31. According to the industry distribution chart, Enwei Pharmaceutical Co ranks #344 out of 995 companies in the Drug Manufacturers industry, placing it in the top 34.6%.
Is Enwei Pharmaceutical Co's Quick Ratio too high?
Enwei Pharmaceutical Co's current Quick Ratio of 2.03 is 36% below median its 10-year median of 3.15. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 4.31. The Drug Manufacturers industry median Quick Ratio is 1.42. Enwei Pharmaceutical Co's value of 2.03 is 43% above this industry median. Based on the distribution chart, Enwei Pharmaceutical Co ranks #344 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Enwei Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enwei Pharmaceutical Co's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enwei Pharmaceutical Co ranks #344 out of 995 companies for Quick Ratio. This puts Enwei Pharmaceutical Co in the upper half of its industry. The industry median Quick Ratio is 1.42. Enwei Pharmaceutical Co's value of 2.03 is 43% above this benchmark. Historically, Enwei Pharmaceutical Co's own Quick Ratio has ranged from 0.74 to 4.31 over the past decade. While the company's 10-year median is 3.15 vs. the industry median of 1.42, Enwei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.42, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enwei Pharmaceutical Co's current Quick Ratio of 2.03 is 43% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Enwei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enwei Pharmaceutical Co's current Quick Ratio is 2.03, which is 36% below median its own 10-year median of 3.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enwei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co (SZSE:301331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.16, compared to a current price of ¥21.84 — trading 22.4% below its estimated fair value. The current Quick Ratio is 2.03, which is 36% below median its 10-year median of 3.15 and 43% above the Drug Manufacturers industry median of 1.42. Enwei Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Enwei Pharmaceutical Co (SZSE:301331), the current Quick Ratio is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enwei Pharmaceutical Co (SZSE:301331) Overvalued in 2026?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥21.84 is trading 22.4% below its estimated GF Value™ of ¥28.16.
GuruFocus considers Enwei Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SZSE:301331:
Quick Ratio: 2.03 (36% below median its 10-year median of 3.15)
GF Value™: ¥28.16 vs. price of ¥21.84 (22.4% below fair value)
Industry Position: 43% above the Drug Manufacturers median (#344 of 995)
No single metric tells the full story. See the SZSE:301331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
76GF Score
Get the complete analysis for SZSE:301331
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301331 has been successfully added to your 
